Ingredients: CBD-CBDA 50/50% in MCT Oil
A combination product of CBD (cannabidiol) and CBDA (cannabidiolic acid), Combo D/A offers numerous benefits for both dogs and cats, largely due to it’s interaction with the endocannabinoid system, which regulates key functions like pain perception, mood, and inflammation. In dogs, research has demonstrated that a 1:1 ratio of CBD to CBDA enhances absorption and retention, making the combination more effective than CBD alone. Studies indicate that CBDA is better absorbed and retained in dogs, and it also boosts CBD absorption, leading to improved outcomes for conditions such as joint discomfort, stress, and cognitive decline. For cats, while they may require higher doses due to differences in metabolism, CBD and CBDA have been found to be safe and well-tolerated, offering potential benefits for similar issues like mobility and behavioral concerns. Research further supports the safety and efficacy of these compounds; for example, studies on cats have shown that CBD and CBDA are well-tolerated at specific doses, while research on dogs has highlighted improvements in mobility and behavior
with supplementation. The inclusion of MCT (medium-chain triglyceride) oil as the base in these products significantly increases the bioavailability of CBD and CBDA, allowing for faster and more efficient absorption in both species. This enhanced absorption means that lower doses may suffice to achieve the desired effects, potentially reducing the risk of side effects while maximizing benefits.
Combo D/A is a product that blends CBD (cannabidiol) and CBDA (cannabidiolic acid), compounds extracted from cannabis plants, aimed at supporting the health of dogs and cats. Research indicates that CBDA, particularly when combined with CBD as in Combo D/A, may help lessen seizure frequency in dogs with epilepsy.
Combo D/A presents a promising avenue for managing epilepsy in dogs, potentially reducing seizure frequency when paired with conventional treatments, as supported by emerging research.
For dogs, Combo D/A holds potential as a treatment for epilepsy by
possibly reducing how often seizures occur. A study published in 2022 in Frontiers in Veterinary Science by Garcia et al. explored this possibility, involving 14 dogs with refractory epilepsy in a 24-week randomized cross-over trial. The dogs received a CBD/CBDA-rich hemp extract, akin to Combo D/A, at a dosage of 2 mg/kg orally every 12 hours
for each 12-week period, compared to a placebo. The findings revealed a notable decrease in seizure frequency, dropping from an average of 8.0 seizures during the placebo phase to 5.0 during the treatment phase. Additionally, the average number of days with epileptic seizures over 12 weeks fell from 5.8 with placebo to 4.1 with treatment. Impressively, 6 out of the 14 dogs experienced a 50% or greater reduction in seizure events while on the treatment, compared to none on placebo, and 5 out of 14 showed a similar reduction in seizure days. The treatment proved generally safe, with only mild side effects like somnolence in 3 dogs and transient ataxia in 4, alongside a slight increase in alkaline phosphatase levels. Importantly, the study found no interference with the metabolism of common anti-seizure medications like zonisamide, phenobarbital, or bromide, suggesting that Combo D/A could serve as a complementary option.